NCT06862531View on ClinicalTrials.gov

A Single-center, Interventional Diagnostic Study With Minimal Risks and Constraints, Aimed at Longitudinally Evaluating Serum Antibody Levels in Patients With COVID-19 According to the Severity of Their Symptoms.

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 25, 2020

Primary Completion Date

November 17, 2020

Study Completion Date

November 17, 2020

Conditions
COVID-19
Interventions
BIOLOGICAL

blood sample

A sample of blood (1mL) was taken

Trial Locations (1)

74370

CH ANnecy-GEnevois (CHANGE), Metz-Tessy

Sponsors

Lead Sponsor

Bioaster
All Listed Sponsors
lead

Bioaster

OTHER

NCT06862531 - A Single-center, Interventional Diagnostic Study With Minimal Risks and Constraints, Aimed at Longitudinally Evaluating Serum Antibody Levels in Patients With COVID-19 According to the Severity of Their Symptoms. | Biotech Hunter | Biotech Hunter